Merck KGaA, Darmstadt, Germany, is reportedly in advanced negotiations to acquire U.S.-based biotech firm SpringWorks Therapeutics. This potential acquisition aims to enhance Merck’s oncology and rare disease treatment portfolio. SpringWorks, valued at approximately $4 billion, specializes in developing therapies for various cancers and rare conditions, including desmoid tumors and uterine cancer.
Details of the Acquisition Talks:
- Who: Merck KGaA, a German healthcare and technology group, and SpringWorks Therapeutics, a U.S. biotech firm.
- What: Advanced discussions for Merck KGaA to acquire SpringWorks, aiming to strengthen Merck’s cancer treatment pipeline.
- When: Reports suggest a potential deal could be finalized in the coming weeks.
